Insider buying last 90 days
No open-market insider purchases were filed for UTHR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every UTHR insider filing, plotted on the chart in Gekko.Open UTHR in Gekko
NASDAQ: UTHR
United Therapeutics (UTHR) Stock Analysis & Forecast
Sep 28 close
$485.54+10.09 (+2.1%)
Gekko Brief
AI summaryUnited Therapeutics shares moved this week on competitive and analyst news. Goldman Sachs initiated coverage with a Sell rating and a $321 price target, citing concerns over the commercial opportunity for upcoming launches, particularly nebulized Tyvaso, and calling the stock overvalued; shares fell 4% on the news. Separately, another analysis maintained a Buy view with a base case valuation of $535 per share, arguing that revenue declines are tied to competition from Liquidia's Yutrepia and are isolated to older formulations rather than the core Tyvaso DPI franchise. The company also outlined a pipeline of 14 prospective product launches spanning pulmonary fibrosis, pulmonary hypertension and organ manufacturing at a healthcare conference, alongside continued share repurchases.
The stock closed at $485.54, up 2.1% on the day, but remains below both its 50-day average of $510.81 and 200-day average of $524.50, with the 50-day below the 200-day. The GekkoIndex reads 67.4, placing it in the Accumulation zone. Price sits 23.6% below Gekko Fair Value of $635.28.
Over the next 20 trading days, the next earnings report is set for 4 November 2026, before the open, falling outside that window; the prior report on 5 August showed EPS of $7.27 against a $6.82 estimate, with a 2.7% reaction. Options activity shows 1 unusual signal in the last 30 days, with put premium of $2,405,220 and no call premium recorded. Seasonally, the next 20 trading days have averaged a 0.5% return over 5 years, rising in 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
United Therapeutics price vs fair value
Close $485.54200-day averageGekko Fair Value $635.28
United Therapeutics quick facts
- Market cap
- $20.61B
- P/E ratio
- 17.7
- Forward P/E
- 16.4
- EPS, TTM
- $26.92
- Revenue, TTM
- $3.15B
- Profit margin
- 41.6%
- Dividend yield
- —
- Beta
- 0.56
- Volume
- 602,465 avg 581,615
- 1-year return
- +14.1%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.2%
- 50-day average
- $510.81
- 200-day average
- $524.50
- Next earnings
- Nov 4 before open
- Shares outstanding
- 42.89M
United Therapeutics swing-trade checklist
United Therapeutics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $485.54 is below the 50-day ($510.81) and 200-day ($524.50) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.4, Accumulation
Reading 67.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
23.6% below
Price is 23.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.5% on average
From this point in the calendar, the next 20 trading days averaged +0.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
United Therapeutics stock chart and price history
United Therapeutics closed at $485.54 on Sep 28, 2026, +14.1% over the past year, inside a 52-week range of $409.07 to $609.35.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.0%
- 3 months
- −10.9%
- 6 months
- −7.1%
- 1 year
- +14.1%
The full UTHR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open UTHR in Gekko
Follow United Therapeutics through every session
Put UTHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track UTHR in GekkoFree for 7 days. No credit card required.
About United Therapeutics
United Therapeutics is a biotechnology company focused on treatments for people with chronic and severe illnesses, some of them life-threatening. It is best known for a group of therapies used in pulmonary arterial hypertension, including Remodulin, Tyvaso, Orenitram and Adcirca, which work to ease symptoms and improve patients' ability to exercise, along with Unituxin, an antibody-based treatment for high-risk neuroblastoma.
Beyond its marketed products, the company runs a pipeline of experimental treatments and devices, among them Tyvaso DPI, the Remunity Pump, RemoPro, Ralinepag and a gene therapy called Aurora-GT aimed at lung blood vessel regeneration, and it is running trials looking at Tyvaso in patients with a form of pulmonary hypertension tied to COPD. It also works with partners such as DEKA Research & Development, MannKind and Arena Pharmaceuticals on delivery devices and drug development, and its business reaches patients in both the United States and other countries.
United Therapeutics was founded in 1996 and is headquartered in Silver Spring, Maryland. Its shares are listed on the NASDAQ under the ticker UTHR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- unither.com
United Therapeutics GekkoIndex: the smart money zone
United Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.4, in the Accumulation zone, up 0.2 points over five sessions.
67.4Accumulation
Up 0.2 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 9 | Too few readings yet | |||
| Accumulation (current zone) | 194 | +0.7% | +1.1% | ||
| Neutral | 426 | +0.9% | +3.9% | ||
| Distribution | 41 | −1.0% | +1.7% | ||
| Selling | 2 | Too few readings yet | |||
Average UTHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the UTHR price, zone by zone.Track UTHR in Gekko
Is United Therapeutics stock overvalued? Gekko Fair Value
United Therapeutics trades 23.6% below Gekko Fair Value of $635.28, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what United Therapeutics shares are worth, recalculated every trading day.
$635.28
Gekko Fair Value, Sep 26, 2026
23.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open UTHR in Gekko
United Therapeutics insider and Congress trading
No open-market insider purchases were filed for United Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in UTHR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for UTHR, plotted on the chart in Gekko.Open UTHR in Gekko
Buybacks
United Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $58.80M
- As a share of market cap
- 0.29%
From company filings.
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Sep 17, $2.41M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds UTHR.
0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
United Therapeutics earnings: next date and track record
United Therapeutics reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $6.46
- Revenue estimate
- $789.7M
4 of 8reports beat the EPS estimate
±5.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- United Therapeutics' Q2 2026 corporate update highlighted significant clinical progress alongside near-term commercial headwinds. The company reported Q2 revenue of approximately $783 million, essentially flat sequentially and below internal expectations; Tyvaso total revenue was $453 million and faced pressure from increased competition in the inhaled prostacyclin category, while Tyvaso DPI showed accelerating momentum. Management emphasized major positive clinical readouts: the ADVANCE OUTCOMES study for ralinepag (PAH) and TETON-1/TETON-2 for nebulized Tyvaso in IPF, leading to recent regulatory submissions (sNDA for nebulized Tyvaso in IPF and NDA for ralinepag in PAH) and planned additional filings (IND for ralinepag DPI and NDA for treprostinil SMI). They expect potential approvals in 2027 for nebulized Tyvaso in IPF, ralinepag in PAH and the SMI device in PAH and PH-ILD, and noted near-complete enrollment in TETON-PPF with a Phase III readout expected in H2 2027. Management reiterated confidence in long-term growth, described the new products as multibillion-dollar opportunities, and said they have roughly doubled the sales force to prepare for IPF and ralinepag launches. They also acknowledged Q2 results were below expectations, will not update or reaffirm prior 2026 revenue growth expectations now, but expect the second half of 2026 to be stronger than the first half.
- Guidance
- Management expects the second half of 2026 to be stronger than the first half, but did not reaffirm or update prior 2026 revenue growth expectations. They expect potential regulatory approvals in 2027 for nebulized Tyvaso in IPF, ralinepag in PAH, and the treprostinil SMI device. The IPF sNDA was submitted in late June; priority review decision pending (6-month review if priority, 10 months otherwise).
- Risks flagged
- Competitive dynamics in the inhaled prostacyclin category putting pressure on nebulized Tyvaso; regulatory uncertainty (priority review decisions, FDA requirements for bridging data for DPI/SMI in IPF); timing risk for approvals and launches; near-term execution risk on commercial acceleration despite expanded sales force; reliance on successful launch execution and market adoption vs. competitors (e.g., JASCAYD).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $7.27 est $6.82 | $783.3M est $804.6M | +2.7% |
| May 6, 2026 | $5.82 est $6.86 | $781.5M est $797.4M | −0.5% |
| Feb 25, 2026 | $7.70 est $7.13 | $790.2M est $813.1M | +6.4% |
| Oct 29, 2025 | $7.16 est $6.89 | $799.5M est $814.8M | +9.2% |
| Jul 30, 2025 | $6.41 est $6.94 | $798.6M est $801.9M | −7.7% |
| Apr 30, 2025 | $6.63 est $6.28 | $794.4M est $778.7M | −2.3% |
| Feb 26, 2025 | $6.19 est $6.27 | $735.9M est $734.7M | −9.5% |
| Oct 30, 2024 | $6.39 est $6.43 | $748.9M est $722.6M | +6.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
United Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for United Therapeutics is $637.92, +31.4% from the last close, from 9 firms rating the stock in the last 90 days.
$637.92consensus 12-month target, +31.4% from the last close
Now $485.54Avg $637.92
Low $321High $704
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $321 | −33.9% |
| Sep 9 | Jefferies | $704 | +45.0% |
| Sep 2 | Wells Fargo | $700 | +44.2% |
| Sep 2 | TD Cowen | $675 | +39.0% |
| Aug 24 | TD Cowen | $675 | +39.0% |
+1.1%average 20-day move after past Accumulation readings
+0.5%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
United Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, United Therapeutics averaged +0.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.8% | 4 of 5 |
| Next 10 trading days | +2.0% | 4 of 5 |
| Next 15 trading days | +2.4% | 4 of 5 |
| Next 20 trading days | +0.5% | 2 of 5 |
| Next 30 trading days | +11.2% | 4 of 5 |
For scale, UTHR’s typical 20-trading-day move in either direction is about 5.2%.
United Therapeutics market cap and key statistics
United Therapeutics’s market cap is $20.61B, with a P/E ratio of 17.7 and revenue of $3.15B over the last twelve months.
Valuation
- Market cap
- $20.61B
- P/E ratio
- 17.7
- Forward P/E
- 16.4
- EPS, TTM
- $26.92
- Gekko Fair Value
- $635.28
Trading
- Volume
- 602,465
- Avg volume, 20 days
- 581,615
- 52-week high
- $609.35
- 52-week low
- $409.07
- Shares outstanding
- 42.89M
Financials
- Revenue, TTM
- $3.15B
- Profit margin
- 41.6%
- Return on equity
- 19.3%
- Quarterly earnings growth, YoY
- +13.4%
Risk and income
- Beta
- 0.56
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±5.2%
United Therapeutics stock news this week
Coverage of United Therapeutics this week reads neutral: 1 positive, 7 neutral and 5 negative headlines.
- After exercising stock options, the CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares.Stock Titan, Sep 28
- Form 4 United Therapeutics Corporation For: 26 September By Investing.comInvesting.com Nigeria, Sep 27
- United Therapeutics: The Market Sees The Erosion, Not The Refill - BuySeeking Alpha, Sep 27
- United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 SharesDefense World, Sep 26
- After exercising stock options, the CEO's family trust sold 9,500 United Therapeutics (UTHR) shares.Stock Titan, Sep 25
- United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney AmbitionsMarketBeat, Sep 25
United Therapeutics peers
United Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| NBIXNeurocrine Biosciences | Buying | 38.6% below |
A peer links to its own page where one exists.
United Therapeutics stock FAQ
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $20.61B at the Sep 28, 2026 close of $485.54, with 42.89M shares outstanding. The shares trade on a P/E ratio of 17.7.
What is the United Therapeutics stock forecast?
The consensus analyst 12-month price target for United Therapeutics is $637.92, +31.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is United Therapeutics stock overvalued or undervalued?
On Gekko’s estimate United Therapeutics is undervalued: the Sep 28, 2026 close of $485.54 is 23.6% below Gekko Fair Value of $635.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does United Therapeutics report earnings next?
United Therapeutics is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $6.46 per share on revenue of $789.7M. United Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 5.5% on average across the report.
What is United Therapeutics’s 52-week high and low?
United Therapeutics’s 52-week high is $609.35 and its 52-week low is $409.07; it closed at $485.54 on Sep 28, 2026, +14.1% over the past year.
Is United Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (seasonality) and 2 as headwinds (trend and smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in United Therapeutics?
Gekko flagged 1 unusual options signal in United Therapeutics over the last 30 days, with $0 of flagged premium in calls and $2.41M in puts. The latest, bearish flow, was on Sep 17, 2026 with $2.41M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See United Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.